Rolls Out New and Improved Ultrasonic Skin Permeation Device
FRANKLIN, Mass., May 9 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONT) announced today that it has introduced its 2nd
Generation SonoPrep(R) skin permeation device for continuous transdermal
glucose monitoring and topical lidocaine delivery. The 2nd Generation
SonoPrep device incorporates several new features suggested by current
SonoPrep customers. It is more portable and ergonomically friendly with
improved features to provide clinician ease of use and patient comfort. New
to the 2nd Generation system is a digital display that monitors system and
patient treatment status. Also new is a removable battery that allows
customers to recharge backup batteries for heavy use conditions. "We are
pleased to launch the new SonoPrep device following a rigorous process of
design, development and validation," stated Scott Kellogg, V.P. of Research
and Development. "Based on input we have received, we designed a more
robust device that is simpler to use and less expensive to manufacture."
The SonoPrep ultrasonic skin permeation employs low frequency
ultrasound to penetrate the skin's outermost layer, the stratum corneum.
This simple and fast (average 15 second) treatment creates an imperceptible
window through the skin that enables molecules to pass through with 100
times greater efficiency than intact skin. The SonoPrep ultrasonic skin
permeation device makes the skin permeable for up to twenty four hours for
continuous non invasive diagnostics such as glucose monitoring and
transdermal drug delivery.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal
science. Sontra's SonoPrep ultrasound-mediated skin permeation technology
combined with technical competencies in transdermal drug formulation,
delivery systems and biosensors is creating a new paradigm in transdermal
drug delivery and diagnosis. The SonoPrep technology is being developed for
several billion dollar market opportunities, including continuous glucose
monitoring and the transdermal delivery of large molecule drugs and
vaccines. Sontra is currently marketing the SonoPrep device and procedure
tray for use with topical lidocaine to achieve rapid (within five minutes)
skin anesthesia.
Contact:
Sean Moran, Sontra Medical CFO
508-530-0334
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks
or registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a
variety of subjects including, for example, the expected technological
advances and availability of the second-generation SonoPrep device, the
expected benefits and efficacy of the SonoPrep device in connection with
diagnostics, vaccine delivery, glucose monitoring and transdermal drug
delivery, Sontra's expected ability to develop, market and sell products
based on its technology; the expected market opportunities, distribution
and market acceptance of the SonoPrep device and technology, and Sontra's
business, research, product development, regulatory approval, marketing and
distribution plans and strategies. Statements that are not historical
facts, including statements about our beliefs and expectations, are
forward-looking statements. Such statements are based on our current
expectations and are subject to a number of factors and uncertainties,
which could cause actual results to differ materially from those described
in the forward-looking statements. The following important factors and
uncertainties, among others, could cause actual results to differ
materially from those described in these forward-looking statements: our
technology is new and we may experience adverse results in research and
development efforts, product development, clinical trials, product
evaluations, commercialization efforts, product distribution and market
acceptance; markets for our products may develop slower than expected, or
not at all; our sales cycle is lengthy and we are still developing sales
and marketing strategies which may or may not prove effective; the SonoPrep
device may not prove effective in connection with diagnostics, vaccine
delivery, glucose monitoring and/or transdermal drug delivery; we may
experience difficulties or delays in obtaining regulatory approvals to
market products resulting from development efforts or difficulties or
delays associated with sources of regulatory-approved transdermal drugs and
vaccines; failure to obtain and maintain patent protection for discoveries
or commercial limitations imposed by patents owned or controlled by third
parties would have an adverse effect on us; we depend upon strategic
partners and third-party distributors to develop, commercialize, market and
sell products based on our work; and we require substantial additional
funding to conduct research and development and to expand
commercialization, distribution and marketing activities. For detailed
information about factors that could cause actual results to differ
materially from those described in the forward-looking statements, please
refer to Sontra's filings with the Securities and Exchange Commission,
including Sontra's most recent Quarterly Report on Form 10-QSB.
Forward-looking statements represent management's current expectations and
are inherently uncertain. We do not undertake any obligation to update
forward-looking statements made by us.
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com/
CONTACT:
Sean Moran, CFO of Sontra Medical,
+1-508-530-0334
|
